Journal articlePreclinical

Thymosin beta 4 promotes corneal wound healing and decreases inflammation in vivo following alkali injury

Experimental eye research, 2002 Feb. Sosne G, Szliter EA, Barrett R and 3 others.

Study type

Journal article

Subjects

Animal / preclinical (no Humans MeSH term)

Journal

Experimental eye research

Published

2002 Feb

PubMed

PMID 11950239 ↗

DOI

10.1006/exer.2001.1125 ↗

Where PepCue cites this

This paper is part of the evidence base behind this profile. Citing a study is not an endorsement of the compound: papers that found no effect are indexed the same way.

Thymosin β-4 →

Indexed under

MeSH terms assigned by the National Library of Medicine.

Administration, TopicalAlkaliesAnimalsAnti-Inflammatory AgentsBurns, ChemicalChemokine CCL2Chemokine CCL3Chemokine CCL4Chemokine CXCL2ChemokinesCorneaCorneal Injuries

Other papers on Thymosin β-4

Randomized controlled trial · 2022

0.1% RGN-259 (Thymosin ß4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial

Journal article · 2012

Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications

Journal article · 2004

Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair

PepCue indexes citation metadata only and does not reproduce abstracts or full text. Read the paper at the source links above. Nothing here is medical advice or a dose recommendation.

Educational and research reference only. Not medical advice, diagnosis, or dosing guidance. Flag an error on this page